Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Saven

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patientsTamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
Molecular Cancer Therapeutics|May 17, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivoChristian A Hassig, Kent T Symons, Xin Guo, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
Leukemia|June 8, 2024
Hairy cell leukemia variant and WHO classification correspondence Re: 5<sup>th</sup> edition WHO classification haematolymphoid tumors: lymphoid neoplasmsMichael Grever, Leslie Andritsos, Mirela Anghelina, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
Blood Cancer Journal|December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaFarhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Blood|April 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variantClive S Zent, Enrico Tiacci, Robert J Kreitman, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patientsTamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
Molecular Cancer Therapeutics|May 17, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivoChristian A Hassig, Kent T Symons, Xin Guo, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
Leukemia|June 8, 2024
Hairy cell leukemia variant and WHO classification correspondence Re: 5<sup>th</sup> edition WHO classification haematolymphoid tumors: lymphoid neoplasmsMichael Grever, Leslie Andritsos, Mirela Anghelina, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
Blood Cancer Journal|December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaFarhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Blood|April 14, 2026
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variantClive S Zent, Enrico Tiacci, Robert J Kreitman, et al.
Pageof 7